Joseph Ogunsulire, MD
Hospitalist · Seneca, SCNPI 1942555073
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 86.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $25,853 and has fallen 95.7% since, to $1,106 in 2025. Among hospitalist clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $167.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$24K
- Calliditas Therapeutics US Inc.$526
- AstraZeneca$392
- Otsuka America Pharmaceutical, Inc.$352
- Travere Therapeutics, Inc.$326
- Ardelyx, Inc.$232
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$16,00057%
- Travel & lodging$4,43116%
- Food & beverage$7,83228%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 73 | $24,361 |
| Calliditas Therapeutics US Inc. | 7 | $526 |
| AstraZeneca(2 entities) | 10 | $392 |
| Otsuka America Pharmaceutical, Inc. | 9 | $352 |
| Travere Therapeutics, Inc. | 6 | $326 |
| Ardelyx, Inc. | 7 | $232 |
| Mallinckrodt Hospital Products Inc. | 5 | $202 |
| AbbVie | 4 | $199 |
| Pfizer | 7 | $187 |
| Aurinia Pharma U.S., Inc. | 3 | $173 |
| GSK | 2 | $149 |
| Amgen | 2 | $136 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| United Therapeutics Corporation | 2 | $121 |
| Novo Nordisk | 1 | $121 |
| Lilly USA, LLC | 1 | $116 |
| Novartis | 6 | $115 |
| Vertex | 1 | $60 |
| Johnson & Johnson | 4 | $56 |
| BD | 2 | $56 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $44 |
| Bayer | 2 | $43 |
| OPKO Pharmaceuticals, LLC | 2 | $38 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Vifor Pharma, Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,301 in reported general payments places this provider in the 95th percentile of 398 hospitalist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 12 | $7,988 |
| EliquisApixaban | 16 | $7,724 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $419 |
| Ondansetron OdtOndansetron | 12 | $234 |
| Pantoprazole Sodium | 49 | $229 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $209 |
| Quetiapine Fumarate | 23 | $207 |
| Morphine Sulfate | 14 | $199 |
| Lorazepam | 23 | $167 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $162 |
| Pregabalin | 11 | $147 |
| Gabapentin | 15 | $136 |
| Atorvastatin Calcium | 17 | $131 |
| Rosuvastatin Calcium | 11 | $109 |
| Donepezil Hcl | 21 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $392 | $7,98812 claims |
| PfizerEliquis | $187 | $7,72416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 398 hospitalist providers in South Carolina.
Other hospitalist in Seneca
- John JohnsonSeneca$7K
- Nathaniel RichardsSeneca$950
- Erika KingMyrtle Beach$19K
- Woodrow CokerCharleston$14K
- Patrick CawleyCharleston$10K
- Christopher VagnoniAnderson$9K
- Anthony ZamchoWest Columbia$7K
- Michael WagnerGreenville$4K
- Phillip WarrCharleston$3K
- Danielle ScheurerCharleston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.